Previous close | 0.9800 |
Open | 0.9800 |
Bid | 0.7500 |
Ask | 1.5000 |
Strike | 2.50 |
Expiry date | 2024-10-18 |
Day's range | 0.9800 - 0.9800 |
Contract range | N/A |
Volume | |
Open interest | 151 |
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET. Checkpoint will also attend in-person one-on-one meetings during the conference. A w
Checkpoint Therapeutics ( NASDAQ:CKPT ) First Quarter 2024 Results Key Financial Results Net loss: US$10.9m (loss...
WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2024, and recent corporate updates. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “Over the past few months, we have worked closely with our third-party contract manufacturing organization (“CMO”) for cosibelimab to resolve